Shang Hai Zheng Quan Bao·2025-11-22 13:47Core Points - After nearly six months of investigation, Jiaying Pharmaceutical received a total fine of 4.9 million yuan for information disclosure violations, along with warnings and regulatory actions from the Guangdong Securities Regulatory Bureau and the Shenzhen Stock Exchange [2][5][9] Group 1: Administrative Penalties - The Guangdong Securities Regulatory Bureau issued an administrative penalty decision, imposing a fine of 1.5 million yuan on Jiaying Pharmaceutical, and additional fines on key executives: 1.6 million yuan on Chairman Li Neng, 1 million yuan on General Manager You Yongping, and 800,000 yuan on former CFO Shi Junping, totaling 4.9 million yuan [5][8] - Warnings and regulatory letters were issued to Jiaying Pharmaceutical and its executives, including Li Neng, You Yongping, Shi Junping, and former board secretary Xiao Qiaoxia [5][9] Group 2: Violations and Findings - The investigation revealed that Li Neng, as the actual controller of Hunan Yaojun Pharmaceutical Co., engaged in improper fund transfers between Jiaying Pharmaceutical and its related party, resulting in a total of approximately 220 million yuan in transactions, which accounted for 28.83% of Jiaying Pharmaceutical's latest audited net assets [7][8] - Jiaying Pharmaceutical failed to disclose related party transactions in a timely manner, including transactions with Gonghe Pharmaceutical, which involved approximately 8.76 million yuan, representing 1.15% of the company's latest audited net assets [7][8] Group 3: Additional Regulatory Actions - The Shenzhen Stock Exchange issued a public reprimand against Jiaying Pharmaceutical and its executives, citing violations related to non-operating fund transfers and improper financial assistance [12][13] - Jiaying Pharmaceutical provided a total of 65 million yuan in financial assistance to three non-related companies, with a maximum daily balance of 40 million yuan, which accounted for 5.24% of the company's latest audited net assets [12]